Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment.
Autor: | Lückerath K; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany. Electronic address: katharina.lueckerath@uk-essen.de., Trajkovic-Arsic M; Division of Solid Tumor Translational Oncology, DKTK and German Cancer Research Center (DKFZ) Partner Side Essen, Hufelandstrasse 15, 45147, Germany; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany., Mona CE; Ahmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, 650 Charles E Young Drive S, Los Angeles, CA 90095, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | PET clinics [PET Clin] 2023 Jul; Vol. 18 (3), pp. 409-418. Date of Electronic Publication: 2023 Mar 27. |
DOI: | 10.1016/j.cpet.2023.02.006 |
Abstrakt: | Fibroblast activation protein (FAP)-radioligand therapy might be effective in some patients without being curative. FAP-radioligands deliver ionizing radiation directly to FAP + cancer-associated fibroblasts and, in some cancers, to FAP + tumor cells; in addition, they indirectly irradiate FAP - cells in tumor tissue via cross-fire and bystander effects. Here, we discuss the potential to improve FAP-radioligand therapy through interfering with DNA damage repair, immunotherapy, and co-targeting cancer-associated fibroblasts. As the molecular and cellular effects of FAP-radioligands on the tumor and its microenvironment have not been investigated yet, we call for future research to close this gap in knowledge, which prevents the development of more effective FAP-radioligand therapies. (Copyright © 2023 Elsevier Inc. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |